<DOC>
	<DOCNO>NCT01876511</DOCNO>
	<brief_summary>This study look whether MK-3475 ( antibody block negative signal T cell ) effective ( anti-tumor activity ) safe three different patient population . These include : 1. patient MSI positive colon cancer , 2. patient MSI negative colon cancer , 3. patient MSI positive cancer .</brief_summary>
	<brief_title>Phase 2 Study MK-3475 Patients With Microsatellite Unstable ( MSI ) Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Arm 1 : Patients MSI positive colorectal cancer 2 . Arm 2 : Patients MSI negative colorectal cancer 3 . Arm 3 : Patients MSI positive noncolorectal cancer 4 . Have measurable disease 5 . ECOG Performance Status 0 1 6 . Adequate organ function define studyspecified laboratory test 7 . Must use acceptable form birth control study 28 day final dose study drug 8 . Signed informed consent form 9 . Willing able comply study procedures 10 . Agree biopsy cancer 11 . Patients colon cancer must receive least two prior cancer therapy regimens . 12 . Patients cancer type must receive least one prior cancer therapy 1 . Patients uncontrolled intercurrent illness , include limited ongoing active infection , systematic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric condition would limit compliance study requirement 2 . Patients chemotherapy biological cancer therapy within 2 week prior first dose study drug 3 . Patients radiation within 2 week prior first dose study drug 4 . Patients undergone major surgery within 4 week dose investigational agent 5 . Patients receive another investigational product investigational device within 4 week prior receive study drug 6 . Patients receive follow concomitant therapy : IL2 , interferon , nonstudy immunotherapy regimen , immunosuppressive agent , investigational therapy chronic use systemic corticosteroid within one week prior first dose study drug 7 . Patients receive live vaccine within 4 week prior dose MK3475 8 . Patients receive growth factor , include limited granulocytecolony stimulate factor ( GCSF ) , granulocyte macrophagecolony stimulate factor ( GMCSF ) , erythropoietin , etc . within 2 week study drug administration 9 . Patient prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiOX40 , antiCD40 , antiCTLA4 antibody 10 . Patients history autoimmune disease : inflammatory bowel disease , ( include ulcerative colitis Crohn 's Disease ) , rheumatoid arthritis , systemic progressive sclerosis ( scleroderma ) , systemic lupus erythmatosus ( SLE ) autoimmune vasculitis , CNS motor neuropathy consider autoimmune origin . 11 . Patients known history infection HIV , hepatitis B , hepatitis C 12 . Patients evidence interstitial lung disease 13 . Systemically active steroid use 14 . Patients home oxygen 15 . Patients oxygen saturation &lt; 92 % room air pulse oximetry 16 . Pregnant lactate 17 . Conditions , include alcohol drug dependence , intercurrent illness would affect patient 's ability comply study visit procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MSI</keyword>
	<keyword>MSS</keyword>
	<keyword>MLH 1</keyword>
	<keyword>MSH 2</keyword>
	<keyword>MSH 6</keyword>
	<keyword>PMS2</keyword>
	<keyword>BRAF pV600E</keyword>
	<keyword>TGFBR2</keyword>
</DOC>